101 related articles for article (PubMed ID: 26676292)
21. Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
Obata J; Matsumoto K; Yamanaka H; Ninomiya A; Nakamura S
Low Urin Tract Symptoms; 2013 Sep; 5(3):145-9. PubMed ID: 26663450
[TBL] [Abstract][Full Text] [Related]
22. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
Maruyama O; Kawachi Y; Hanazawa K; Koizumi K; Yamashita R; Sugimura S; Honda S; Sugiyama Y; Saitoh T; Noto K
Int J Urol; 2006 Oct; 13(10):1280-5. PubMed ID: 17010005
[TBL] [Abstract][Full Text] [Related]
23. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial.
Gotoh M; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Origasa H;
BJU Int; 2005 Sep; 96(4):581-6. PubMed ID: 16104914
[TBL] [Abstract][Full Text] [Related]
24. [Clinical effects of naftopidil on nocturia associated with benign prostatic hyperplasia].
Sugino Y; Fukuzawa S; Takeuchi H; Taki Y; Hashimura T; Soeda T; Araki I
Hinyokika Kiyo; 2003 Aug; 49(8):445-9. PubMed ID: 14518379
[TBL] [Abstract][Full Text] [Related]
25. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
[TBL] [Abstract][Full Text] [Related]
26. Does prostate volume affect the efficacy of α1D/A: Adrenoceptor antagonist naftopidil?
Tanuma Y; Tanaka Y; Takeyama K; Okamoto T
Urol Ann; 2016; 8(1):20-5. PubMed ID: 26834396
[TBL] [Abstract][Full Text] [Related]
27. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia.
Griwan MS; Karthikeyan YR; Kumar M; Singh BJ; Singh SK
Urol Ann; 2014 Jul; 6(3):181-6. PubMed ID: 25125888
[TBL] [Abstract][Full Text] [Related]
28. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A;
Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723
[TBL] [Abstract][Full Text] [Related]
29. [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
Kamimura N; Hatakeyama S; Kudo S; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Kawaguchi T; Takahashi S; Ohyama C
Hinyokika Kiyo; 2011 Feb; 57(2):71-6. PubMed ID: 21412038
[TBL] [Abstract][Full Text] [Related]
30. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study.
Komiya A; Suzuki H; Awa Y; Egoshi K; Onishi T; Nakatsu H; Ohki T; Mikami K; Sato N; Araki K; Ota S; Naya Y; Ichikawa T
Int J Urol; 2010 Jun; 17(6):555-62. PubMed ID: 20370847
[TBL] [Abstract][Full Text] [Related]
31. Randomized Controlled Trial to Treat Benign Prostatic Hyperplasia with Overactive Bladder Using an Alpha-blocker Combined with Anticholinergics.
Nishizawa O; Yamaguchi O; Takeda M; Yokoyama O;
Low Urin Tract Symptoms; 2011 Apr; 3(1):29-35. PubMed ID: 26676349
[TBL] [Abstract][Full Text] [Related]
32. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
33. A Slow Stream Is Pathophysiologically Related to a Poor Response to α1-Adrenoceptor Therapy in the Treatment of Storage Symptoms Associated With Benign Prostatic Hyperplasia.
Matsukawa Y; Takai S; Asai K; Kasugai S; Narita H; Komatsu T; Kashiwagi Y; Kato M; Yamamoto T; Gotoh M
Urology; 2015 Sep; 86(3):558-64. PubMed ID: 26189139
[TBL] [Abstract][Full Text] [Related]
34. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy.
Yamaguchi S; Osanai H; Numata A; Watanabe M; Kakizaki H
Int J Urol; 2013 May; 20(5):513-9. PubMed ID: 23078534
[TBL] [Abstract][Full Text] [Related]
35. Effects of Doxazosin on Alpha 1-Adrenergic Receptors in Prostates with Benign Prostatic Hyperplasia.
Lee HN; Lee KS; Lee SY; Shim BS; Lee YS; Hong JH; Lim BH; Lee HM
Low Urin Tract Symptoms; 2013 May; 5(2):82-9. PubMed ID: 26663375
[TBL] [Abstract][Full Text] [Related]
36. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
[TBL] [Abstract][Full Text] [Related]
37. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
[TBL] [Abstract][Full Text] [Related]
38. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
[TBL] [Abstract][Full Text] [Related]
39. Cutoff level of prostate volume to predict the efficacy of α1-D/A adrenoceptor antagonist, naftopidil.
Tanuma Y; Tanaka Y; Okamoto T
Urol Ann; 2021; 13(3):296-300. PubMed ID: 34421268
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose--comparison between 75 and 50 mg.
Oh-oka H
Urol Int; 2009; 82(2):136-42. PubMed ID: 19321997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
